Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

This study has been completed.
Sponsor:
Information provided by:
Ethical Oncology Science
ClinicalTrials.gov Identifier:
NCT00572637
First received: December 12, 2007
Last updated: May 19, 2010
Last verified: May 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2010
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)